Australian research has found the new combination of ibrutinib and venetoclax is effective in patients with relapsed or refractory mantle cell lymphoma. The phase 2 study, presented recently at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, is the first in the world to report on patients receiving full clinical doses of the ...
Synergy in new drug combo for lymphoma
By Mardi Chapman
11 Jul 2017